Crigler-Najjar syndrome – Diagnostics – Overview of Information and Clinical Research

Getting diagnosed with Crigler-Najjar syndrome involves a series of specific tests and examinations that help doctors understand whether a newborn’s persistent jaundice is more than just a temporary concern. Early and accurate identification of this rare condition is essential because it determines the treatment path and can help prevent serious complications that may affect the child’s brain and overall development.

Introduction: Who Should Undergo Diagnostics and When

Crigler-Najjar syndrome is an extremely rare condition that requires careful attention from the very first days of a baby’s life. Any newborn showing signs of jaundice—which is the yellowing of the skin and the whites of the eyes—should be monitored closely. While jaundice is quite common in newborns and usually disappears within the first week of life, babies with Crigler-Najjar syndrome experience persistent jaundice that does not resolve on its own and often worsens over time.^[1]

Parents should seek diagnostic testing if their newborn has jaundice that lasts beyond the first week or becomes more intense rather than fading. This is especially important if there is a family history of liver conditions or unexplained jaundice in previous children. The condition can affect anyone, but families with a history of genetic liver diseases should be particularly vigilant. Because Crigler-Najjar syndrome is inherited when both parents carry a mutation in the same gene, families with consanguinity—meaning parents who are related by blood—face a higher risk.^[5]

Early diagnosis is critical because the buildup of unconjugated bilirubin—the toxic form of bilirubin that has not been processed by the liver—can lead to a dangerous condition called kernicterus. Kernicterus is a form of brain damage that occurs when excessive bilirubin accumulates in the brain and nerve tissues. This complication can cause irreversible neurological problems, including hearing loss, intellectual disability, and movement disorders. Therefore, prompt diagnostic testing is not just advisable but essential to prevent life-threatening consequences.^[1]

⚠️ Important

If your newborn develops severe jaundice that appears within the first few days after birth and continues to intensify, do not wait to see if it resolves naturally. Contact your child’s healthcare provider immediately. This persistent yellowing could be a sign of Crigler-Najjar syndrome or another serious liver condition that requires urgent medical attention.

Diagnostic Methods Used to Identify Crigler-Najjar Syndrome

Diagnosing Crigler-Najjar syndrome involves multiple steps, starting with a physical examination and followed by several laboratory tests. The process aims to confirm the presence of elevated bilirubin levels, determine the type of bilirubin that is accumulating, and rule out other conditions that might cause similar symptoms.^[2]

Physical Examination

The diagnostic journey typically begins with a thorough physical examination of the newborn. Doctors look for the characteristic yellow discoloration of the skin and eyes, which is the hallmark of jaundice. They also assess the baby’s overall health, checking for signs of lethargy, poor feeding, or unusual muscle tone. These symptoms can indicate that bilirubin levels are dangerously high and may already be affecting the nervous system.^[1]

Liver Blood Tests

Blood tests are the cornerstone of diagnosing Crigler-Najjar syndrome. These tests measure the amount of bilirubin in the blood and help distinguish between different types of bilirubin. A crucial test is the split bilirubin test, which separates total bilirubin into two categories: conjugated and unconjugated bilirubin. In children with Crigler-Najjar syndrome, the vast majority of bilirubin is unconjugated, meaning it has not been processed by the liver enzyme that normally converts it into a non-toxic form.^[18]

In type 1 Crigler-Najjar syndrome, total bilirubin levels are usually extremely high, often exceeding 345 micromoles per liter (20 milligrams per deciliter). This represents a dangerous level that puts the child at immediate risk for brain damage. In type 2, bilirubin levels are lower but still significantly elevated, typically ranging between 60 and 340 micromoles per liter (3.5 to 20 milligrams per deciliter). These measurements help doctors understand the severity of the condition and guide treatment decisions.^[5]^[9]

Urine Tests

Doctors also conduct urine tests to look for traces of bilirubin or other substances that might indicate how the liver is functioning. In Crigler-Najjar syndrome, the urine analysis can reveal patterns that differ from other liver conditions, helping to narrow down the diagnosis.^[18]

Genetic Testing

Because Crigler-Najjar syndrome is caused by mutations in the UGT1A1 gene, genetic testing can provide definitive confirmation of the diagnosis. This test looks for specific changes in the DNA that prevent the body from producing the enzyme needed to break down bilirubin. Genetic testing can also determine whether a child has type 1 or type 2 Crigler-Najjar syndrome, which is important because the two types require different approaches to treatment.^[3]

Genetic counseling is often recommended for families after a diagnosis is confirmed. This service helps parents understand how the condition was inherited, what it means for their child’s future, and what the risks might be for any future children they may have.^[3]

Liver Biopsy

In some cases, doctors may perform a liver biopsy to examine a small sample of liver tissue under a microscope. This test can help confirm that the liver’s structure is normal and that the problem lies specifically with the enzyme that processes bilirubin. A liver biopsy involves inserting a needle into the liver to remove a tiny piece of tissue, which is then analyzed in a laboratory.^[18]

Enzyme Assay

An enzyme assay is a specialized test that measures the activity of the UGT enzyme in the liver. In type 1 Crigler-Najjar syndrome, this test shows that the enzyme is completely absent or has virtually no activity. In type 2, the enzyme is present but works at less than 10% of normal capacity. This test is crucial for distinguishing between the two types and understanding the severity of the condition.^[2]

Phenobarbital Response Test

One of the most important diagnostic tools is the phenobarbital response test. Phenobarbital is a medication that can stimulate the liver to produce more of the enzyme needed to process bilirubin. In children with type 2 Crigler-Najjar syndrome, taking phenobarbital causes a noticeable drop in bilirubin levels. However, in type 1, this medication has no effect because the enzyme is entirely missing. This difference in response helps doctors definitively classify which type of Crigler-Najjar syndrome a child has, which is essential for planning long-term care.^[5]^[18]

Bile Analysis

In some cases, doctors may analyze a sample of bile, the digestive fluid produced by the liver. In healthy individuals, bile contains primarily conjugated bilirubin, which is the processed, non-toxic form. In children with type 1 Crigler-Najjar syndrome, bile is almost entirely composed of unconjugated bilirubin with only traces of the conjugated form. This finding confirms that the liver is unable to perform its normal function of converting bilirubin.^[9]

Differential Diagnosis

Because persistent jaundice can be caused by many different conditions, doctors must carefully rule out other possibilities before confirming a diagnosis of Crigler-Najjar syndrome. Other conditions that can cause similar symptoms include hemolytic anemia (where red blood cells break down too quickly), Gilbert’s syndrome (a milder genetic condition), biliary atresia (a blockage in the bile ducts), and various infections. The combination of blood tests, genetic testing, and response to phenobarbital helps distinguish Crigler-Najjar syndrome from these other conditions.^[5]

Diagnostics for Clinical Trial Qualification

For families considering enrollment in clinical trials for Crigler-Najjar syndrome, there are additional diagnostic requirements beyond those used for standard medical care. Clinical trials often test experimental treatments such as gene therapy, which aims to restore the missing enzyme function in the liver. Because these trials are carefully controlled scientific studies, researchers need precise information about each patient’s condition before they can participate.^[6]

The standard criteria for enrolling patients in clinical trials typically include confirmation of the diagnosis through genetic testing. Researchers need to verify that the patient has mutations in the UGT1A1 gene and that these mutations are causing the symptoms. Blood tests showing persistently high levels of unconjugated bilirubin are also required to establish the severity of the disease and ensure that the patient would benefit from the experimental treatment.^[6]

Clinical trials may also require detailed assessments of liver function beyond basic blood tests. These can include imaging studies such as ultrasound or MRI scans to examine the structure and health of the liver. Researchers want to ensure that the liver is otherwise healthy and capable of responding to the experimental treatment. Additionally, neurological evaluations may be conducted to assess whether the patient has already experienced any brain damage from high bilirubin levels.^[6]

Some trials have specific age requirements or restrictions based on the severity of the condition. For example, a gene therapy trial might only accept patients with type 1 Crigler-Najjar syndrome who require daily phototherapy and who have not yet undergone liver transplantation. The eligibility criteria vary depending on what the trial is testing and what questions the researchers are trying to answer.^[6]

Before a patient can be enrolled in a clinical trial, extensive documentation is required. This includes complete medical records showing the history of the condition, all previous treatments, and the results of all diagnostic tests. Families may also need to provide information about their family history and any other health conditions that might affect the trial results. This thorough documentation ensures that researchers have a complete picture of each participant’s health status.^[6]

⚠️ Important

If you are considering enrolling your child in a clinical trial, discuss the specific diagnostic requirements with the research team early in the process. Some tests may take time to schedule and complete, and gathering all necessary medical records can be time-consuming. Starting this process early ensures you don’t miss important enrollment windows.

Prognosis and Survival Rate

Prognosis

The outlook for children with Crigler-Najjar syndrome depends almost entirely on which type they have. Type 1 is the more severe form and carries a much more serious prognosis. Most children with type 1 who do not receive treatment do not survive past childhood due to the toxic effects of extremely high bilirubin levels on the brain and nervous system. Even with regular phototherapy treatment, children with type 1 remain at constant risk of developing kernicterus, particularly during periods of illness or stress when bilirubin levels can spike suddenly.^[1]^[18]

The prognosis improves significantly with proper treatment. Children who receive consistent phototherapy from birth can maintain lower bilirubin levels and avoid immediate brain damage. However, as children with type 1 grow older, phototherapy becomes less effective because thickened skin blocks the light. This means that by the time they reach adolescence or early adulthood, phototherapy alone may no longer be sufficient to keep bilirubin at safe levels. Without a liver transplant, most people with type 1 Crigler-Najjar syndrome develop brain damage over time, even with dedicated treatment.^[1]

The prognosis for type 2 Crigler-Najjar syndrome is much better. Children with type 2 have a normal life expectancy and typically experience only mild symptoms. While they do have persistent jaundice that may worsen during periods of stress, illness, or fasting, their bilirubin levels usually remain below the threshold that causes brain damage. Most people with type 2 can manage their condition with medication and do not require liver transplantation. They can lead full, active lives with minimal medical intervention.^[1]^[2]

Survival Rate

For children with type 1 Crigler-Najjar syndrome who do not receive a liver transplant, the average life expectancy is approximately 30 years. This limited lifespan is primarily due to the cumulative effects of high bilirubin levels on the brain and nervous system. Even with daily phototherapy, the risk of developing kernicterus remains present throughout life, and any interruption in treatment—whether due to illness, equipment failure, or other circumstances—can lead to a dangerous spike in bilirubin levels.^[1]

Liver transplantation dramatically improves survival rates for type 1 patients. A successful liver transplant essentially cures the condition by providing a healthy liver that can produce the missing enzyme. Children who receive liver transplants at a young age, before significant brain damage has occurred, have survival rates comparable to other liver transplant recipients and can expect to live well into adulthood and beyond. However, transplantation carries its own risks and requires lifelong immunosuppression to prevent organ rejection.^[6]

For type 2 Crigler-Najjar syndrome, the survival rate is similar to that of the general population. Because the condition is much milder and does not typically cause life-threatening complications, people with type 2 have a normal life expectancy. Permanent neurological damage is rare in type 2, and the need for liver transplantation is extremely uncommon. Most individuals with type 2 live full, healthy lives with minimal medical intervention beyond occasional medication adjustments.^[2]

It is important to note that survival and prognosis also depend on how quickly the condition is diagnosed and how consistently treatment is maintained. Early diagnosis and immediate initiation of phototherapy can prevent the initial brain damage that sometimes occurs in the first weeks of life. Families who maintain strict adherence to treatment schedules and who work closely with their medical team tend to have better outcomes overall.^[1]

#1 Clinical Trials Search in Europe

Crigler-Najjar syndrome – Diagnostics

Introduction: Who Should Undergo Diagnostics and When